Cargando…

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer

SIMPLE SUMMARY: The discovery of actionable oncogenic driver mutations in non-small-cell lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful disease. New targeted therapies are being developed and tested in early phase clinical trials rapidly. We summarize emerging fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shenduo, de Camargo Correia, Guilherme Sacchi, Wang, Jing, Manochakian, Rami, Zhao, Yujie, Lou, Yanyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251928/ https://www.ncbi.nlm.nih.gov/pubmed/37296863 http://dx.doi.org/10.3390/cancers15112899

Ejemplares similares

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
por: Majeed, Umair, et al.
Publicado: (2021)

First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report
por: Majeed, Umair, et al.
Publicado: (2023)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Emerging therapeutic agents for advanced non-small cell lung cancer
por: Chen, Ruqin, et al.
Publicado: (2020)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Seegobin, Karan, et al.
Publicado: (2021)

Immunotherapies targeting stimulatory pathways and beyond
por: Marin-Acevedo, Julian A., et al.
Publicado: (2021)

Survival of Black and White Patients With Stage IV Small Cell Lung Cancer
por: Shi, Huashan, et al.
Publicado: (2021)

Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer
por: Zhou, Kexun, et al.
Publicado: (2021)

Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature
por: Seegobin, Karan, et al.
Publicado: (2020)

Crizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with ALK‐positive non‐small‐cell lung cancer: Case report and review of the literature
por: Wiest, Nathaniel E., et al.
Publicado: (2021)

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
por: Soyano, Aixa E., et al.
Publicado: (2018)

Genomic landscape of lung adenocarcinomas in different races
por: Shi, Huashan, et al.
Publicado: (2022)

Emerging Lung Cancer Therapeutic Targets Based on the Pathogenesis of Bone Metastases
por: Oyewumi, Moses O., et al.
Publicado: (2014)

Trends in participant race and sex reporting in lung cancer phase III clinical trials
por: Aslam, Faaiq N., et al.
Publicado: (2023)

Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers
por: Lou, Yanyan, et al.
Publicado: (2018)

Brief report: risk stratification following curative therapy for stage I NSCLC
por: Butts, Emily, et al.
Publicado: (2023)

A Case of Full Recovery from Prolonged Cardiac Arrest after Infusion with Paclitaxel and Pembrolizumab
por: Sh Ahmed, Omar, et al.
Publicado: (2022)

Targeted therapies for advanced non-small cell lung cancer
por: Ai, Xiaojuan, et al.
Publicado: (2018)

The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
por: Yuan, Min, et al.
Publicado: (2019)

Recent advances of novel targeted therapy in non-small cell lung cancer
por: Katzel, Jed A, et al.
Publicado: (2009)

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
por: Stinchcombe, Thomas E
Publicado: (2007)

Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer
por: Wakelee, Heather, et al.
Publicado: (2018)

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
por: Salgia, Ravi, et al.
Publicado: (2021)

Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma
por: Pal, Krishnendu, et al.
Publicado: (2022)

Emerging therapies for non-small cell lung cancer
por: Zhang, Chao, et al.
Publicado: (2019)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context
por: Le, Alexander D, et al.
Publicado: (2017)

Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
por: Gullapalli, Sneha, et al.
Publicado: (2020)

Recent advances in non-small cell lung cancer targeted therapy; an update review
por: Araghi, Mahmood, et al.
Publicado: (2023)

Emerging Therapies in Thoracic Malignancies—Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non–Small Cell Lung Cancer
por: Sepesi, Boris, et al.
Publicado: (2020)

Salvage surgery following downstaging of advanced non‐small cell lung cancer by targeted therapy
por: Li, Kuo, et al.
Publicado: (2021)

Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets
por: Aguiar, Pedro Nazareth, et al.
Publicado: (2017)

Targeted therapies in non-small cell lung cancer
por: Kyle, Fiona, et al.
Publicado: (2008)

The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer
por: Wong, Annick
Publicado: (2017)

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

Small Cell Lung Cancer: Emerging Targets and Strategies for Precision Therapy
por: Patel, Shruti R., et al.
Publicado: (2023)

Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017)

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
por: Wu, Shang-Gin, et al.
Publicado: (2018)

Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
por: Dong, Jingsi, et al.
Publicado: (2019)

Editorial: New Advances in Non-small Cell Lung Cancer Management: Immune Modulation and Targeted Therapies
por: Berghmans, Thierry, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8jmopmi99lgsb1mnfrsi0snquj